Perbak Capital Partners LLP acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,984 shares of the life sciences company's stock, valued at approximately $1,201,000.
Other institutional investors also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new stake in Illumina in the fourth quarter valued at about $32,000. Versant Capital Management Inc grew its position in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina in the 4th quarter valued at approximately $45,000. Assetmark Inc. raised its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in Illumina during the fourth quarter worth $48,000. 89.42% of the stock is owned by institutional investors and hedge funds.
Illumina Stock Performance
Shares of NASDAQ:ILMN traded up $1.37 on Friday, hitting $77.88. 1,190,941 shares of the company were exchanged, compared to its average volume of 2,283,628. The company's 50 day moving average price is $80.07 and its two-hundred day moving average price is $115.86. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm has a market capitalization of $12.33 billion, a price-to-earnings ratio of -10.14, a PEG ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.
Analyst Upgrades and Downgrades
ILMN has been the subject of several recent research reports. TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and lowered their target price for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Guggenheim dropped their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Citigroup cut their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Morgan Stanley lowered their target price on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a report on Tuesday, February 11th. Finally, HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price on the stock. in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and an average price target of $137.55.
Get Our Latest Report on ILMN
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
